Combining dasatinib and IFN-α in CML – immunomodulatory effects linked to treatment response and adverse events
We pooled 100,000 cells from the 12 scRNA+TCRab-seq samples from peripheral blood from three time points (n=4, samples at 0, 3, and 12 months) to understand the landscape of immune subsets in CML during the course of dasatinib+IFN-α treatment
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001009085 | Illumina HiSeq 2500 | 48 | |
EGAD00001009086 | Illumina NovaSeq 6000 | 48 |
Publications | Citations |
---|---|
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
J Clin Invest 132: 2022 e152585 |
4 |